Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
John Orwin
AddedMar 31, 2024
UpdatedMay 1, 2026
John Orwin

John Orwin

Board Member, Travere Therapeutics

John Orwin's Career

Travere Therapeutics
Travere Therapeutics

San Diego, CA, US

Board Member· Board
Affymax
Affymax

Cupertino, CA, US

Board Member· Board
AnaptysBio
AnaptysBio

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

John Orwin's Career

Travere Therapeutics
Travere Therapeutics
Public$792.5M4622008San Diego, CA, US
Board Member· Board

Leadership at Travere Therapeutics

Roy BaynesRoy BaynesBoard Member
Martin ShkreliMartin ShkreliFounder
Gary LyonsGary LyonsBoard Member
Jeffrey A. MecklerJeffrey A. MecklerBoard Member
Suzanne BruhnSuzanne BruhnBoard Member
Steve AselageSteve AselageBoard Member
Affymax
Affymax
$173M3752001Cupertino, CA, US
Board Member· Board

Leadership at Affymax

Prashant TyagiPrashant TyagiFounder
John Peter WalkerJohn Peter WalkerBoard Member
Jonathan M CouchmanJonathan M CouchmanBoard Member
Allan BaxterAllan BaxterBoard Member

Similar to Affymax

AffigenAffigenSt. Louis, MO, USCancer Therapiesest. 2016AffigenSt. Louis, MO, US · est. 2016

St. Louis startup developing targeted therapies for tumor identification and treatment.

Series A · $17M6
AffaMed TherapeuticsAffaMed TherapeuticsNew York City, NY, USPharmaceuticalsest. 2019AffaMed TherapeuticsNew York City, NY, US · est. 2019

AffaMed Therapeutics: A clinical-stage biopharmaceutical company innovating transformative drugs.

Series B · $170M175
AimMax TherapeuticsAimMax TherapeuticsDurham, NC, USPharmaceuticalsest. 2017AimMax TherapeuticsDurham, NC, US · est. 2017

AimMax Therapeutics: Pioneering pharmaceutical research and development.

Angel · $75k7
Apexian PharmaceuticalsApexian PharmaceuticalsIndianapolis, IN, USDrugs, Pharmaceuticalsest. 2005Apexian PharmaceuticalsIndianapolis, IN, US · est. 2005

Apex Therapeutics, based in Indianapolis, US, develops and markets drugs for cancer and eye diseases.

Angel · $6.9M5
AnaptysBio
AnaptysBio
Public$85.9M962005San Diego, CA, US
Board Member· Board

Leadership at AnaptysBio

Dennis FentonDennis FentonBoard Member
Heath LukatchHeath LukatchBoard Member
Jamie TopperJamie TopperBoard Member
J. Anthony WareJ. Anthony WareBoard Member
Andrea CubittAndrea CubittCo-Founder
Hollings RentonHollings RentonBoard Member

Similar to AnaptysBio

NantkwestNantkwestCulver City, CA, USCancer Treatment, Immunotherapyest. 2014NantkwestCulver City, CA, US · est. 2014

ImmunityBio, Inc.: A US-based biotech firm specializing in immunotherapy for cancer and infectious diseases.

Public · $103.5M51
INmune BioINmune BioBoca Raton, FL, USCancer Treatmentsest. 2015INmune BioBoca Raton, FL, US · est. 2015

INmune Bio Inc., a US-based clinical-stage biotech firm, specializes in developing cancer treatments.

Public · $103.2M17
Santa Ana BioSanta Ana BioAlameda, CA, USBiologics, Therapiesest. 2021Santa Ana BioAlameda, CA, US · est. 2021

Santa Ana Bio designs precision biologics using deep cell profiling tech, specializing in autoimmune diseases.

Series A · $35.3M18
Anthera PharmaceuticalsAnthera PharmaceuticalsHayward, CA, USPharmaceuticalsest. 2004Anthera PharmaceuticalsHayward, CA, US · est. 2004

Anthera Pharmaceuticals: A US biopharma firm specializing in inflammation and autoimmune disease treatments.

Public · $101.5M21

People Similar to John Orwin

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao